28 JULY 2005

NEW ZEALAND GAZETTE, No. 112

Triamcinolone; in aqueous nasal sprays delivering up to
55 micrograms per actuation when the maximum daily
dose is no greater than 220 micrograms and the medicine
has received the consent of the Minister or the
Director-General to its distribution as a pharmacy-only
medicine

Medicines for General Sale

Please note that the following medicines are no longer
classified as prescription medicines, restricted medicines or
pharmacy-only medicines. As such, they are now available
for general sale.

Acetylcysteine; for external use; for oral use in medicines
containing 1 gram or less per recommended daily dose

Aciclovir; for external use for the treatment of herpes
labialis in medicines containing 5% or less and tubes
containing 3 grams or less

Bamyphylline

Benzamine

Benzyl benzoate

Bifonazole; for external use in medicines for tinea pedis
only or in shampoos containing 1% or less

Butyl aminobenzoate; in medicines for dermal use
containing 2% or less

Collagen; except in injections or implantations for tissue
augmentation or cosmetic use

Dextromethorphan; in liquid form containing 0.25% or
less or in solid dose form containing 15 milligrams
or less per dose form when in packs containing not
more than 600 milligrams and with a recommended daily
dose of not more than 120 milligrams

Dichlofenthion

Diprophylline

Ephedra navadensis

Fluorides; in pastes, gels or powders for cleaning the
teeth containing 0.1% or less; in parenteral nutrition
replacement preparations; in oral hygiene products
other than pastes, gels or powders for cleaning the
teeth containing 220 milligrams or less per litre or per
kilogram and in packs containing not more than
120 milligrams of total fluoride; in other medicines
containing 15 milligrams or less per litre or per kilogram

Folic acid; for oral use in medicines containing 500
micrograms or less per recommended daily dose

Folinic acid; for oral use in medicines containing 500
micrograms or less per recommended daily dose

Gadobenic acid

Gadobutrol

Guaiphenesin; for oral use in medicines containing 2% or
less or 200 milligrams or less

Hyaluronic acid; except in injections or implantations for
tissue augmentation or cosmetic use

Hydroquinone; for external use in hair preparations
containing 1% or less

Hylan polymer; except injections or implantations for tissue
augmentation or cosmetic use

Hyoscyamus niger; in packs containing 30 micrograms or
less of total solanaceous alkaloids

Ibuprofen; for external use; for oral use in solid dose form
containing 200 milligrams or less per dose form when in
packs containing not more than 25 dose units and when
in medicines which have received the consent of the
Minister or the Director-General to their sale as general
sale medicines and which are sold in the manufacturer’s
original pack

Injectable medicines; except when specified in the First
Schedule to the Medicines Regulations

Ketoprofen; for external use

Mandelic acid

Monosulfiram

Nicotine; for transdermal use or in chewing gum, lozenges
or sublingual tablets

Oxedrine; in medicines containing 30 milligrams or less per
recommended daily dose

Phenylephrine; for nasal or ophthalmic use in medicines
containing 1% or less; for oral use in medicines
containing 50 milligrams or less per recommended daily
dose and in packs containing 250 milligrams or less of
phenylephrine per pack

Piridoxine; in medicines containing 200 milligrams or less
per recommended daily dose

Reproterol

Sabadilla; in packs containing 1.8 milligrams or less with
a recommended daily dose of not more than 0.6
milligrams of total alkaloids

Salicylic acid; in medicines containing 40% or less

Silver; in oral solutions containing 0.3% or less or other
medicines containing 1% or less

Terebene

Tetrastarch

Trichloroacetic acid; for external use in medicines
containing 12.5% or less for the treatment of warts other
than anogenital warts

Regulation 20 of the Medicines Regulations 1984 requires
that all medicines sold without a practitioner’s prescription
must include a consumer information panel on the label.
Further, all material changes to a medicine (including changes
to labelling) must be notified to the Director-General of
Health in accordance with section 24 of the Medicines Act
1981.

Dated this 21st day of July 2005.

DON MATHESON, Deputy Director-General, Public Health
Directorate.

go4874

Inland Revenue

Tax Administration Act 1994

Notice of Intention to Impose Late Filing Penalty

If you were required to file a 2005 IR 3 individual tax return
or IR 4 company tax return by 7 July 2005, and you have
not yet filed this return, a late filing penalty may be charged
after 30 days from the date of this notice.

To avoid this penalty being charged, please file your return
within 30 days of the date of this notice.

This notice does not apply to taxpayers who have an
extension of time.

If you require a 2005 IR 3 or IR 4 tax return, please phone
INFOexpress on 0800 257 773 or visit our web site at
www.ird.govt.nz

Dated at Wellington this 28th day of July 2005.

INLAND REVENUE.

Address for Service: P.O. Box 2198, Wellington.

go4599